



## **Combined Ordinary and Extraordinary General Meeting on April 29<sup>th</sup> 2009**

Procedures for obtaining preparatory documents

PARIS, March 25<sup>th</sup>, 2009 – BioAlliance Pharma's shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 2.00 pm on April 29<sup>th</sup> 2009 at the company's head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France).

The official notice of the Meeting will be published in the French Republic's *Bulletin des Annonces Légales Obligatoires* ("Bulletin of Mandatory Legal Announcements") dated March 25<sup>th</sup>, 2009 and contains the agenda, the draft resolutions and information on attendance and voting procedures. It can be viewed on the company's web site at:

<http://www.bioalliancepharma.com/eng/Investisseurs/Shareholders-Meetings>

Notice of the meeting will be published in an official journal of legal announcements on April 14<sup>th</sup> 2009.

Documents related to the meeting will be made available to shareholders from April 8<sup>th</sup> onwards, under the conditions set out in the current legislation.

Shareholders may, in accordance with Articles R.225-88 and R.225-89 of the French Commercial Code, consult the afore-mentioned documents (together with the information specified in Articles R.225-81 and R.225-83 of the said Code) at the company's head office or request supply of the said documents and information by post/mail to a duly indicated postal/ mailing or electronic address by writing to BioAlliance Pharma (Direction Financière – 49 boulevard du Général Martial Valin, F-75015 Paris, France), faxing to +33 1 45 58 08 81 or sending an e-mail to [ag2009@bioalliancepharma.com](mailto:ag2009@bioalliancepharma.com) after April 8<sup>th</sup> 2008.

**About BioAlliance Pharma**

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading European player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

**BioAlliance Pharma SA**

Dominique Costantini, President and CEO  
Tel.: +33 1 45 58 76 01  
[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)

Nicolas Fellmann, CFO  
Tel.: +33 1 45 58 71 00  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

**ALIZE RP**

Caroline Carmagnol  
Tel.: +33 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)